rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ELDN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of...

      Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treate...

      Oct 26Business InsiderELDN
      Breakthrough T1D Funded Clinical Trial Testing Islet Cell Transplantation with Eledon's Tegoprubart Expands to Include People with Type 1 Diabetes and Kidney Disease
      Oct 21Yahoo FinanceELDN
      Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

      IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation. Details of the presentation are b

      Oct 5Yahoo FinanceELDN
      Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)

      Detailed price information for Lexeo Therapeutics Inc (LXEO-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailELDNEWTXLXEO
      Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)

      Detailed price information for Amgen Inc (AMGN-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailELDN
      Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22
      Sep 22Seeking AlphaELDN
      Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ)
      Sep 22Seeking AlphaELDN
      Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

      Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an app...

      Sep 22Business InsiderELDN
      Eledon’s tegoprubart shows kidney function advantage in phase 2 trial
      Sep 22Investing.comELDN
      Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

      IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026. Details of the presentation are below: Oral Presentation Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evalua

      Sep 9Yahoo FinanceELDN
      Eledon submits IND for tegoprubart islet cell transplant study
      Sep 3Investing.comELDN
      Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart

      Eledon Pharmaceuticals (ELDN) has submitted an investigational new drug application to the US Food a

      Sep 3Yahoo FinanceELDN
      Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

      IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant First patient dosed under compassionate use of tegoprubart for conversion from tacrolimus in islet cell transplant recipients with calcineurin inhibitor related kidney dysfunction First patients dosed under compa

      Sep 3Yahoo FinanceELDN

      This is the newest page. Registered accounts read further back.